Article
Novo Nordisk: obesity drugs priority over century-old focus on insulin
Rating:
0.0
Views:
55
Likes:
1
Library:
1
Novo Nordisk said on Thursday treating obesity with its weight-loss drug Wegovy as a precursor to type 2 diabetes was a priority for the company, continuing the Danish drugmaker's shift away from its century-long focus on insulin.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value